US Drug Recall Register
Class II · Moderate risk Terminated Initiated May 4, 2016 (10 years ago)

Octreotide Acetate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impuities/Degradation Specifications

What was recalled

OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-01.

Recalling firm
Fresenius Kabi USA, LLC
NDC code
63323-365-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0866-2016

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Octreotide recalls

See all
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc D-0519-2026
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc NDC 0480-9262-08 D-0406-2026
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc NDC 0480-9259-08 D-0405-2026
Class II · Moderate risk Ongoing

Octreotide Acetate for Injectable Suspension

Reason Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Teva Pharmaceuticals USA, Inc NDC 0480-9257-08 D-0404-2026
Class I · High risk Terminated

Octreotide Acetate Injection 500 mcg/mL

Reason Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.

Viatris Inc D-0058-2023